The Food and Drug Administration has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for ...
Omeros transitions from a distressed microcap to a small-cap following a transformative Novo Nordisk deal and FDA approval of ...
Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this success ...
Danish drugmaker Novo Nordisk (NOV: N) has secured US approval for an oral version of Wegovy (semaglutide), expanding access ...
Zacks.com on MSN
Can Amgen's MariTide Take on Leaders in the Obesity Space?
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo ...
Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...
Bagsværd, Denmark, 10 September 2025 – Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards ...
Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...
Danish pharmaceutical multinational Novo Nordisk is expanding its presence in inherited blood disorder treatments ...
Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo ...
Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the second quarter, but management reduced 2025 guidance to 8%-14% sales growth and 10%-16% operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback